Currently, clinical trials using CXCL10 antibody (MDX-1100), are looking promising in patients with ulcerative colitis and rheumatoid arthritis [51], promoting investigations of the role of CXCR3 in chronic colitis. Here, CXCL10 is linked to ulcerative colitis.